Your source for expert insights into the future of healthcare. Factide delivers in-depth coverage of biotechnology, medical engineering, and the AI-driven innovations transforming global health outcomes with precision and speed.
Intervene Immune's TRIIM platform, which focuses on thymus regeneration, has advanced to the XPRIZE Healthspan semifinals, challenging conventional wisdom about immune aging.
The death of Lenia Watson-Burton highlights risks of unregulated 'lunchtime lipo' procedures, including counterfeit materials and unverified practitioner credentials. Dr. Hollenbeck warns of long-term consequences from discounted treatments.
2026 sees MAHA-driven policy shifts in synthetic dyes, SNAP restrictions, and ultraprocessed foods as West Virginia and California lead state-level reforms.
The 2025–2030 US Dietary Guidelines recommend increased protein, full-fat dairy, and reduced ultra-processed foods, but face criticism over industry ties and health equity gaps.
A new gamified app, Sugar Slay, aims to help young adults manage Type 1 diabetes by integrating with health trackers and using daily missions to encourage consistent glucose monitoring.
AHA highlights how poverty and weight stigma perpetuate obesity disparities. Learn about systemic solutions to address this crisis.
New research identifies a 10-hour weekly gaming threshold linked to higher BMI and poor diet in university students, though causation cannot be proven.
The atherosclerotic cardiovascular disease market is projected to grow steadily through 2034, with Alnylam Pharmaceuticals leading innovation in RNA interference therapies for disease management.
The health coach market is projected to grow through 2033, with Omada Health leading digital solutions for chronic disease prevention and management.
New research reveals foam reorganization mirrors AI learning mathematics, offering insights into adaptive systems. Theoretical implications for biology and AI models.
Explore the policy challenges of alcohol-free drinks as they gain popularity, balancing public health benefits against marketing risks and regulatory gaps.
FDA bans compounded GLP-1s in 2025 due to health risks; compounded drugs remain available illegally. Learn about the dangers and FDA recommendations.
